{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:05:11Z","timestamp":1793034311792,"version":"4.5.0"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Synthetic opioids have been associated globally with adverse effects in drug users. The nitazene group of drugs is a relatively new addition to the synthetic opioid class emerging in Europe in 2019. Some nitazenes have been shown to be more potent than fentanyl. Overdose clusters in heroin users in Dublin (57 cases) and Cork (20 cases), Ireland, in November and December 2023, respectively, prompted a rapid response from a number of Irish laboratories to identify the substance(s) of concern. Light brown (tan) powders were obtained from cases associated with overdoses, and the results from these analyses by collaboration of four laboratories are reported here. The samples were found to contain <jats:italic>N<\/jats:italic>\u2010pyrrolidino protonitazene (protonitazepyne), caffeine, paracetamol, benzoic acid and mannitol.<\/jats:p>","DOI":"10.1002\/dta.3707","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:50:47Z","timestamp":1716252647000},"page":"350-357","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Identification of <i>N<\/i>\u2010pyrrolidino protonitazene in powders sold as heroin and associated with overdose clusters in Dublin and Cork, Ireland"],"prefix":"10.1002","volume":"17","author":[{"given":"Sarah","family":"Killoran","sequence":"first","affiliation":[{"name":"Forensic Science Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-0721","authenticated-orcid":false,"given":"Sin\u00e9ad","family":"McNamara","sequence":"additional","affiliation":[{"name":"HSE National Drug Treatment Centre Laboratory  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1613-3305","authenticated-orcid":false,"given":"Pierce","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"Discipline of Pharmacology and Therapeutics, School of Medicine Trinity College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O'Brien","sequence":"additional","affiliation":[{"name":"School of Chemistry Trinity College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Lakes","sequence":"additional","affiliation":[{"name":"Forensic Science Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"EMCDDA.Injecting drug use in Europe \u2013 the current situation (European Drug Report 2023).https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2023\/injecting-drug-use_en(accessed on February 9th 2024)."},{"key":"e_1_2_5_3_1","unstructured":"Report on good practices of synthetic opioid preparedness and needs and challenges in EU Member States Deliverable D3.2Inari Viskari and Tuukka Tammi(accessed on February 9th 2024 via the HRB National Drugs Library) https:\/\/www.drugsandalcohol.ie\/34028\/1\/SO-PREP_Good-practices-of-synthetic-opioid-preparedness-and-needs-and-challenges-in-EU-Member-States.pdf"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16420"},{"key":"e_1_2_5_5_1","unstructured":"Advisory Council on the Misuse of Drugs.2023. ACMD advice on 2\u2010benzyl benzimidazole and piperidine benzimidazolone opioidshttps:\/\/www.gov.uk\/government\/publications\/acmd-advice-on-2-benzyl-benzimidazole-and-piperidine-benzimidazolone-opioids\/acmd-advice-on-2-benzyl-benzimidazole-and-piperidine-benzimidazolone-opioids-accessible-version(accessed on January 14th 2024)."},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010023\u201006451\u20102"},{"key":"e_1_2_5_7_1","unstructured":"ACMD Advisory Council on the Misuse of Drugs.2023. Addendum to ACMD's report on the use and harms of 2\u2010benzyl benzimidazole (\u2018nitazene\u2019) and piperidine benzimidazolone (\u2018brorphine\u2010like\u2019) opioidshttps:\/\/assets.publishing.service.gov.uk\/media\/651ee06b79fc5800146396d1\/Addendum_on_ACMD_s_advice_on_2-benzyl_benzimidazole_and_piperidine_benzimidazolone_opioids_6_Oct_2023.pdf(accessed on 9th February 2024)."},{"key":"e_1_2_5_8_1","unstructured":"The Center for Forensic Science Research & Education (CFSRE). New nitazene analogue N\u2010pyrrolidino protonitazene impacting Drug markets in North America and Europe.https:\/\/www.cfsre.org\/nps-discovery\/public-alerts\/new-nitazene-analogue-n-pyrrolidino-protonitazene-impacting-drug-markets-in-north-america-and-europe(accessed on January 14th 2024)."},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204\u2010022\u201003276\u20104"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2084406"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.110686"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.legalmed.2023.102216"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000970"},{"key":"e_1_2_5_14_1","unstructured":"Government of Ireland.Misuse of Drugs Act 1977.https:\/\/www.irishstatutebook.ie\/eli\/1977\/act\/12\/enacted\/en\/html (accessed April 10 2024)."},{"key":"e_1_2_5_15_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).European Database on New Drugs (EDND) reports: EDND\u2010CR\u20102023\u2010863 (19\/07\/2023) EDND\u2010CR\u20102023\u20101050 (13\/09\/2023) and EDND\u2010CR\u20102023\u20101207 (16\/11\/2023)."},{"key":"e_1_2_5_16_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.(11 December 2023) EU early warning system intensive monitoring. Protonitazepyne under intensive monitoring as of 11 December 2023. ID: EU\u2010EWS\u2010IM\u20102023\u20100007 EMCDDA."},{"key":"e_1_2_5_17_1","unstructured":"HSE drugs.ie on X (formerly known as Twitter).https:\/\/twitter.com\/drugsdotie\/status\/1722643609344729245(accessed on 9th February 2024)."},{"key":"e_1_2_5_18_1","unstructured":"HSE Ireland on X (formerly known as Twitter).https:\/\/twitter.com\/HSELive\/status\/1723091240692883835(accessed on 9th February 2024)."},{"key":"e_1_2_5_19_1","unstructured":"HSE drugs.ie on X (formerly known as Twitter).https:\/\/twitter.com\/drugsdotie\/status\/1723110167812657508(accessed on 9th February 2024)."},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1639"},{"key":"e_1_2_5_21_1","unstructured":"HSE DRUGS.ie and poisons information service of Ireland. synthetic opioid preparedness. Fact sheet for medical care providers. February 2024https:\/\/www.drugsandalcohol.ie\/40531\/1\/Synthetic_opiod_for_medical_practitioners.pdf accessed April 10 2024)."}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T21:18:58Z","timestamp":1760390338000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/dta.3707"],"URL":"https:\/\/doi.org\/10.1002\/dta.3707","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"2024-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}